Parecer de pré-exame
#6.23
07/21/2026
RPI 2898
Application data
Number
112021005614Type
Filing
Publication
PCT
US2019052997 Patent grant document available
We have the complete official document for this filing, as published by INPI.
Access the documentThe INPI issued a technical opinion on patentability. The applicant must respond for examination to continue.
Latest action published by the INPI: 07/21/2026. We update with every new RPI gazette, published weekly.
Applicants
VIELA BIO, INC.
US
Inventors
E. G. (pessoa física)
US
G. I. (pessoa física)
US
J. L. (pessoa física)
US
J. D. (pessoa física)
US
K. S. (pessoa física)
US
L. W. (pessoa física)
US
M. A. (pessoa física)
US
W. R. (pessoa física)
US
IPC Classification
Priority claims
US
62/736,851 · 09/26/2018
US
62/747,552 · 10/18/2018
US
62/758,060 · 11/09/2018
US
62/853,575 · 05/28/2019
Abstract
A presente invenção refere-se a uma molécula Tn3 específica para CD40L humano e seus usos terapêuticos.
Publications in the Brazilian Industrial Property Gazette (RPI).
#6.23
07/21/2026
RPI 2898
#25.7
02/03/2026
RPI 2874
#1.3
06/29/2021
RPI 2634
#1.1
04/13/2021
RPI 2623
From the same holder
Same category
Patent monitoring
Receive alerts on INPI events, decisions, and expiry dates for your portfolio.